JP2015518494A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518494A5
JP2015518494A5 JP2015511473A JP2015511473A JP2015518494A5 JP 2015518494 A5 JP2015518494 A5 JP 2015518494A5 JP 2015511473 A JP2015511473 A JP 2015511473A JP 2015511473 A JP2015511473 A JP 2015511473A JP 2015518494 A5 JP2015518494 A5 JP 2015518494A5
Authority
JP
Japan
Prior art keywords
patent document
products
international
publication
application publication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518494A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/033991 external-priority patent/WO2013169406A1/en
Publication of JP2015518494A publication Critical patent/JP2015518494A/ja
Publication of JP2015518494A5 publication Critical patent/JP2015518494A5/ja
Pending legal-status Critical Current

Links

JP2015511473A 2012-05-07 2013-03-27 室温安定性ドロナビノールカプセルの製造および包装 Pending JP2015518494A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643713P 2012-05-07 2012-05-07
US61/643,713 2012-05-07
PCT/US2013/033991 WO2013169406A1 (en) 2012-05-07 2013-03-27 Manufacturing and packaging room temperature stable dronabinol capsules

Publications (2)

Publication Number Publication Date
JP2015518494A JP2015518494A (ja) 2015-07-02
JP2015518494A5 true JP2015518494A5 (enExample) 2016-04-21

Family

ID=49513014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511473A Pending JP2015518494A (ja) 2012-05-07 2013-03-27 室温安定性ドロナビノールカプセルの製造および包装

Country Status (5)

Country Link
US (1) US8741341B2 (enExample)
EP (1) EP2846782A4 (enExample)
JP (1) JP2015518494A (enExample)
CA (1) CA2872248A1 (enExample)
WO (1) WO2013169406A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
ES2835720T3 (es) * 2014-06-11 2021-06-23 Poviva Corp Composiciones de alimentos y bebidas infusionadas con agentes activos lipófilos y métodos de uso de las mismas
EP3164141B1 (en) 2014-06-11 2020-11-11 Poviva Corp. Food and beverage compositions infused with lipophilic active agents and methods of use thereof
CA3176674A1 (en) 2015-05-18 2016-11-24 5071, Inc. Homogenous cannabis compositions and methods of making the same
ES2938560T3 (es) * 2015-05-28 2023-04-12 Radius Pharmaceuticals Inc Formulaciones de cannabinoides estables
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
EP3737371A4 (en) * 2018-01-10 2021-10-06 Benuvia Therapeutics, LLC DRONABINOL STABILIZATION PROCESSES
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
US20230001128A1 (en) * 2019-11-25 2023-01-05 Gary Stephen Shuster Aerosolization systems, methods, and apparatuses
WO2021216475A1 (en) 2020-04-20 2021-10-28 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents
US20230390209A1 (en) * 2020-10-23 2023-12-07 Fuji Capsule Co., Ltd. Cannabidiol-containing seamless soft capsule
EP4591855A1 (en) 2024-01-23 2025-07-30 Echo Pharmaceuticals B.V. Stable dronabinol compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4917671U (enExample) * 1972-05-17 1974-02-14
JPS60183374A (ja) * 1984-02-24 1985-09-18 大日本印刷株式会社 脱酸素密封包装物の製造法
HRP20040816A2 (en) * 2002-04-03 2005-06-30 Solvay Pharmaceuticals B.V. Stabilized natural cannabinoid formulation
PL215220B1 (pl) * 2002-08-14 2013-11-29 Gw Pharma Ltd Ciekly preparat farmaceutyczny
JP4341835B2 (ja) * 2004-04-13 2009-10-14 日本化薬株式会社 カプセル剤の保存容器並びに保存方法
US7633097B2 (en) 2004-09-23 2009-12-15 Philips Lumileds Lighting Company, Llc Growth of III-nitride light emitting devices on textured substrates
EA200701246A1 (ru) * 2004-12-09 2008-06-30 Инсис Терапьютикс, Инк. Стабильные при комнатной температуре составы дронабинола
JP5053544B2 (ja) * 2004-12-28 2012-10-17 株式会社カネカ 還元型補酵素q10の保存方法
WO2007109824A1 (en) * 2006-03-24 2007-10-04 Ian Simon Tracton Stable packaged dosage form and process therefor
US8039509B2 (en) * 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
CA2698752A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US20120043242A1 (en) * 2010-08-19 2012-02-23 Andrew David Hospodor Medicinal cannabis fatty foodstuff
EP2621509A4 (en) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHOD OF USE

Similar Documents

Publication Publication Date Title
JP2015518494A5 (enExample)
EP3778608C0 (en) POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
JP2014532727A5 (enExample)
HUE053357T2 (hu) Gyógyszerészeti készítmény és annak beadásai
JP2014519662A5 (enExample)
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2012126725A5 (enExample)
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
IL216006A (en) Substituted aromatic compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medications
MX2019012757A (es) Composicion farmaceutica para administracion oral que comprende enzalutamida.
JP2016527801A5 (enExample)
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
EP3476864A4 (en) ANTIBODIES AGAINST ETAR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
HUE054609T2 (hu) Elkészítési eljárás hagyományos kínai gyógyszer mikrocsepp pilulához, és a hagyományos kínai gyógyszer mikrocsepp pilula, amely ennek az eljárásnak az alkalmazásával van elkészítve
RU2015136958A (ru) 2-арил-2, 4-дигидрокси-2, 5-дигидро-3-гетерил-5-оксо-1н-пиррол-1-ил-4-метилбелзолсульфаниламиды, обладающие анальгетической активностью
BR112013024196A2 (pt) complexos de gálio, composições farmacêuticas e métodos de uso
JP2019518052A5 (enExample)
JP2013505038A5 (enExample)
BR112015028551A2 (pt) derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos
TH160505A (th) สารประกอบและวิธีสำหรับเสริมการตอบสนองด้วยภูมิคุ้มกันโดยกำเนิดให้เพิ่มขึ้น
TH126235A (th) สารดัดแปรผลึกที่คงตัวของ dopc
冯育军 Self-destruction in the Mirror: A Lacanian Psychoanalysis of Death of A Salesman
TH1701003316A (th) สูตรผสมของ 2-(เทิร์ต-บิวทิลอะมิโน)-4-((1r,3r,4r)-3-ไฮดรอกซี-4-เมทิลไซโคลเฮกซิลอะมิโน)-ไพริมิดีน-5-คาร์บอกซาไมด์
Wang et al. Statins do not improve lung function decline in COPD?